HealthCare Global Enterprises (HCG), a leading cancer care network, has partnered with Trucan Diagnostics, a cutting-edge cancer diagnostics startup, to revolutionize cancer detection and treatment monitoring. This collaboration seeks to validate next-generation diagnostic tests to precisely detect primary, recurrent, and metastatic cancers and enable personalized treatment response predictions.

As part of the partnership, HCG and Trucan will conduct extensive validation studies on Trucan’s innovative diagnostic tests. These tests leverage next-generation sequencing and biomarker-driven diagnostics to enhance accuracy in detecting cancers and assessing treatment responses. The goal is to generate robust clinical data to establish the efficacy of these tools, paving the way for their integration into routine cancer care.

Speaking about the collaboration, Dr. BS Ajaikumar, Executive Chairman of HCG, said, “This partnership underscores our commitment to advancing precision oncology. Together with Trucan, we aim to provide oncologists with cutting-edge tools to improve patient outcomes and reduce treatment burdens.”

Trucan Diagnostics CEO, Dr. Arjun Nair, added, “Our biomarker-driven diagnostic solutions are designed to bring accuracy and personalization to cancer care, minimizing ineffective therapies while optimizing patient well-being.”

This partnership marks a significant step in leveraging innovation to redefine cancer diagnostics, offering oncologists advanced tools to tailor treatments and enhance patient care.